ECMO支持治疗新型冠状病毒肺炎患者的抗真菌药物应用要点

Keypoint of Antifungal Application for ECMO Supported COVID-19 Patients

体外膜氧合支持治疗是目前新型冠状病毒肺炎(COVID-19)患者最强有力的呼吸/心脏支持手段。COVID-19的危重型患者病程时间较长,前期有使用激素治疗的可能,较多患者均会存在细胞免疫抑制的情况,尤其是需要入住ICU进行有创机械通气的患者,继发真菌感染的情况值得关注。本文从ECMO的概述、抗真菌药物PK/PD及抗真菌药物应用要点等进行讨论,为COVID-19后期继发真菌感染患者的个体化药物治疗提供参考。

Extracorporeal membrane oxygenation is currently the most powerful means of respiratory/cardiac support for COVID-19 patients.The critically ill patients with COVID-19 have a longer time of disease course and may be treated with cocorticoids in the early stage.Cellular immunosuppression may occur in many patients,especially those who need to be admitted to the ICU for mechanical ventilation.The fungal infection of these patients in the later stages is worthy of attention.This article discussed the overview of ECMO,PK/PD of antifungal drugs and keypoint of application.Provided a reference for the individualized drug treatment of patients with secondary fungal infection in the late COVID-19.